Myconostica Ltd, a UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces that it has launched a new version of its of MycAssay™ Pneumocystis product in the European Community and Canada. 

MycAssay™ Pneumocystis is a molecular diagnostic test for the detection of Pneumocystis jirovecii DNA in lower respiratory tract samples. The new kit has improved clinical performance and increased analytical sensitivity. The kit is designed to be used by qualified laboratory professionals; the results provided by MycAssay™ Pneumocystis aid physicians to make a diagnosis in patients suspected of having an infection caused by Pneumocystis jirovecii.

When MycAssay™ Pneumocystis is used in conjunction with Myconostica's fungal DNA extraction system, MycXtra^®, a result
can be obtained within 3 hours of sample receipt. MycAssay™ Pneumocystis provides rapid and accurate results to physicians, enabling appropriate drug treatments to be administered thereby improving patient outcomes.

Myconostica also announces that it has signed an agreement with Bactus AB (Bactus AB, Lunastigen 3, SE 141 44 Huddinge, Sweden, www.bactus.se, contact: Jan Skansen) to act as the exclusive distributor of its products in Sweden and Finland.

Dr. John Thornback, Myconostica’s Chief Business Officer, said “We have a programme of constant improvement and standardisation of our assays and, in addition to improved clinical performance of the new kit, both MycAssay™ Aspergillus
and MycAssay™ Pneumocystis now have identical PCR component volumes, sample volumes, pathogen and internal control fluorophores, and similar run parameters”

For further information please contact:

Myconostica Ltd
Heidi Wahlefeld-Moghimi
Heidi.Wahlefeld@myconostica.co.uk
+44 (0)161 998 7239

Media Enquiries:
Cardew Group
Tim Robertson
+44 (0)20 7930 0777

About Myconostica Ltd.

Myconostica Ltd, a UK-based medical diagnostic company, specialises in rapid and highly specific tests for life-threatening fungal infections. Traditional methods of the detection of fungal infections are well documented as being relatively insensitive and slow.  Tests provided by Myconostica aim to allow healthcare professionals to rapidly identify patients infected thus enabling clinicians to prescribe appropriate drug therapy.
Myconostica is developing and commercialising a portfolio of real-time molecular diagnostic tests for life-threatening fungal infections. Over 10 million people are at risk of these infections each year in Europe and North America alone.
 
On the web: www.myconostica.co.uk